Duloxetine: a review of its pharmacology and use in chronic pain management
- PMID: 20921842
- DOI: 10.1097/AAP.0b013e3181df2645
Duloxetine: a review of its pharmacology and use in chronic pain management
Abstract
Duloxetine is a serotonin and norepinephrine reuptake inhibitor that possesses antidepressant and pain-relieving properties. Compared with other antidepressants, it has a high affinity for both norepinephrine and serotonin reuptake transporters, which are relatively balanced. Analgesic onset has been observed within the first week of administration in randomized controlled trials and is likely obtained by enhancing the tone of the descending pain inhibition pathways of the central nervous system. Randomized trials have documented significant analgesic effects for managing chronic pain associated with fibromyalgia and diabetic peripheral neuropathic pain. Studies have also suggested that pain associated with major depressive disorder can be reduced with this medication. Modest effects for headache, osteoarthritic pain, and pain secondary to Parkinson disease have also been documented, but data are obtained from single-blinded or open-label trials that require further corroboration with larger randomized studies. Duloxetine has not yet been directly compared with other antidepressants or anticonvulsants for the treatment of pain syndromes.
Similar articles
-
Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor.Am J Health Syst Pharm. 2005 Dec 1;62(23):2481-90. doi: 10.2146/ajhp050006. Am J Health Syst Pharm. 2005. PMID: 16303903 Review.
-
Duloxetine pharmacology: profile of a dual monoamine modulator.CNS Drug Rev. 2002 Winter;8(4):361-76. doi: 10.1111/j.1527-3458.2002.tb00234.x. CNS Drug Rev. 2002. PMID: 12481192 Free PMC article. Review.
-
A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.Neurology. 2006 Oct 24;67(8):1411-20. doi: 10.1212/01.wnl.0000240225.04000.1a. Neurology. 2006. PMID: 17060567 Clinical Trial.
-
Duloxetine: a new selective and dual-acting antidepressant.Expert Opin Pharmacother. 2006 Mar;7(4):421-7. doi: 10.1517/14656566.7.4.421. Expert Opin Pharmacother. 2006. PMID: 16503814 Review.
-
Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.J Clin Psychiatry. 2003;64 Suppl 13:30-7. J Clin Psychiatry. 2003. PMID: 14552654 Review.
Cited by
-
The narcotic bowel syndrome: a recent update.Am J Gastroenterol Suppl. 2014 Sep 10;2(1):22-30. doi: 10.1038/ajgsup.2014.6. Am J Gastroenterol Suppl. 2014. PMID: 25207609 Review.
-
Assessment of the Management of Patients with Chronic Pain Referred to a Specialized Pain Unit: A Cross-Sectional Multicenter Study (the DUO Project).J Clin Med. 2022 Jun 22;11(13):3586. doi: 10.3390/jcm11133586. J Clin Med. 2022. PMID: 35806871 Free PMC article.
-
From neurotransmitters to networks: Transcending organisational hierarchies with molecular-informed functional imaging.Neurosci Biobehav Rev. 2023 Jul;150:105193. doi: 10.1016/j.neubiorev.2023.105193. Epub 2023 Apr 21. Neurosci Biobehav Rev. 2023. PMID: 37086932 Free PMC article. Review.
-
Predictors of duloxetine adherence and persistence in patients with fibromyalgia.J Pain Res. 2012;5:193-201. doi: 10.2147/JPR.S31800. Epub 2012 Jun 22. J Pain Res. 2012. PMID: 22792005 Free PMC article.
-
Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms.Curr Neuropharmacol. 2019;17(2):184-196. doi: 10.2174/1570159X15666170915143217. Curr Neuropharmacol. 2019. PMID: 28925884 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical